Underuse of anticoagulation in patients with atrial fibrillation

References

• Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–847.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–2375.
   PubMed Web of Science ®Google Scholar
• Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–125.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76.
   PubMed Web of Science ®Google Scholar
• Lee WC, Lamas GA, Balu S, et al. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J Med Econ. 2008;11(2):281–298.
   PubMedGoogle Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–988.
   PubMed Web of Science ®Google Scholar
• Miller PS, Andersson FL, Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke. 2005;36(2):360–366.
   PubMed Web of Science ®Google Scholar
• Penado S, Cano M, Acha O, et al. Atrial fibrillation as a risk factor for stroke recurrence. Am J Med. 2003;114(3):206–210.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Albers GW. Optimizing oral anticoagulation in managed care. Am J Manag Care. 2004;10(14 Suppl):S474–7.
   PubMed Web of Science ®Google Scholar
• Hess PL, Mirro MJ, Diener HC, et al. Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, 2012. Am Heart J. 2014;168(3):239–47 e1.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Mueller I, Bassand J-P, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. Plos One. 2013;8(5):e63479.
   PubMed Web of Science ®Google Scholar
• Lip GY, Rushton-Smith SK, Goldhaber SZ, et al. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The Prospective Global Anticoagulant Registry in the FIELD-Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2015;8(2 Suppl 1):S12–20.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Schmalowsky J, Pittrow D, et al. Management of patients with atrial fibrillation by primary-care physicians in Germany: 1-year results of the ATRIUM registry. Clin Cardiol. 2014;37(5):277–284.
   PubMed Web of Science ®Google Scholar
• Huisman MV, Rothman KJ, Paquette M, et al. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF Registry, Phase II. Am J Med. 2015;128(12):1306–13 e1.
   PubMed Web of Science ®Google Scholar
• Gomes T, Mamdani MM, Holbrook AM, et al. Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med. 2012;172(21):1687–1689.
   PubMedGoogle Scholar
• Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3(6):624–631.
   PubMed Web of Science ®Google Scholar
• Cohen BJ, Pauker SG. How do physicians weigh iatrogenic complications? J Gen Intern Med. 1994;9(1):20–23.
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–2870.
   PubMed Web of Science ®Google Scholar
• Lip GY, Frison L, Halperin JL, et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41(12):2731–2738.
   PubMed Web of Science ®Google Scholar
• Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395–401.
   PubMed Web of Science ®Google Scholar
• Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713–719.
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867.
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 2001;38(4):1231–1266.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Arch Intern Med. 2012;172(8):623–631. discussion 31-3
   PubMedGoogle Scholar
• PRADAXA® (dabigatran etexilate mesylate) capsules for oral use. Full prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2015.
   Google Scholar
• XARELTO® (rivaroxaban) tablets, for oral use. Full prescribing information. Titusville, NJ: Janssen Pharmaceutical, Inc; 2015.
   Google Scholar
• SAVAYSA® (edoxaban) tablets for oral use. Full prescribing information. Parsippany, NJ: Daiichi Sankyo, Inc; 2015.
   Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• ELIQUIS® (apixaban) tablets for oral use. Full prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; 2015.
   Google Scholar
• Lip GY. The role of aspirin for stroke prevention in atrial fibrillation. Nat Reviews Cardiol. 2011;8(10):602–606.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817.
   PubMed Web of Science ®Google Scholar
• Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503.
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation. 2001;104(17):2118–2150.
   PubMed Web of Science ®Google Scholar
• Baczek VL, Chen WT, Kluger J, et al. Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. BMC Fam Pract. 2012;13:5.
   PubMed Web of Science ®Google Scholar
• Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–45 e4.
   PubMed Web of Science ®Google Scholar
• Cowan C, Healicon R, Robson I, et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart. 2013;99(16):1166–1172.
   PubMed Web of Science ®Google Scholar
• Chan PS, Maddox TM, Tang F, et al. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J Cardiol. 2011;108(8):1136–1140.
   PubMed Web of Science ®Google Scholar
• O’Brien EC, Kim S, Hess PL, et al. Effect of the 2014 atrial fibrillation guideline revisions on the proportion of patients recommended for oral anticoagulation. JAMA Intern Med. 2015;175(5):848–850.
   PubMed Web of Science ®Google Scholar
• Holt TA, Hunter TD, Gunnarsson C, et al. Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. Br J Gen Pract. 2012;62(603):e710–7.
   PubMed Web of Science ®Google Scholar
• Granziera S, Bertozzo G, Pengo V, et al. To treat or not to treat very elderly naive patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort. Intern Emerg Med. 2015;10(7):795–804.
   PubMed Web of Science ®Google Scholar
• Jespersen SF, Christensen LM, Christensen A, et al. Use of oral anticoagulation therapy in atrial fibrillation after stroke: results from a nationwide registry. Thrombosis. 2013;2013:1–7.
   PubMedGoogle Scholar
• Bahri O, Roca F, Lechani T, et al. Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. J Am Geriatr Soc. 2015;63(1):71–76.
   PubMed Web of Science ®Google Scholar
• Thompson LE, Maddox TM, Bradley SM, et al. Gender differences in the use of anti-coagulant for atrial fibrillation: a report from the NCDR®. Circulation. 2015;132:A14594.
   Web of Science ®Google Scholar
• Lopes RD, Shah BR, Olson DM, et al. Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry. Stroke. 2011;42(12):3477–3483.
   PubMed Web of Science ®Google Scholar
• Hsu JC, Chan PS, Tang F, et al. Oral anticoagulant prescription in patients with atrial fibrillation and a low risk of thromboembolism: insights from the NCDR PINNACLE registry. JAMA Intern Med. 2015;175(6):1062–1065.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology. 2012;14(10):1385–1413.
   PubMed Web of Science ®Google Scholar
• Cohen N, Almoznino-Sarafian D, Alon I, et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke. 2000;31(6):1217–1222.
   PubMed Web of Science ®Google Scholar
• Bungard TJ, Ghali WA, McAlister FA, et al. Physicians’ perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation. CMAJ. 2001;165(3):301–302.
   PubMed Web of Science ®Google Scholar
• Gattellari M, Worthington J, Zwar N, et al. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians. Stroke. 2008;39(1):227–230.
   PubMed Web of Science ®Google Scholar
• Choudhry NK, Anderson GM, Laupacis A, et al. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ (Clinical Research Ed). 2006;332(7534):141–145.
   PubMed Web of Science ®Google Scholar
• O’Brien EC, Simon DN, Allen LA, et al. Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014;168(4):487–494.
   PubMed Web of Science ®Google Scholar
• Kirley K, Qato DM, Kornfield R, et al. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5):615–621.
   PubMed Web of Science ®Google Scholar
• Marzec LN, Goscch KL, Chan PS, et al. Abstract 14902: The introduction of novel oral anticoagulants has improved overall oral anticoagulants rates in atrial fibrillation: insights from the NCDR PINNACLE Registry. Circulation. 2015;132(Suppl 3):A14902.
   Google Scholar
• Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes. 2013;6(5):567–574.
   PubMed Web of Science ®Google Scholar
• Sen S, Dahlberg KW. Physician’s fear of anticoagulant therapy in nonvalvular atrial fibrillation. Am J Med Sci. 2014;348(6):513–521.
   PubMed Web of Science ®Google Scholar
• Gross CP, Vogel EW, Dhond AJ, et al. Factors influencing physicians’ reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther. 2003;25(6):1750–1764.
   PubMed Web of Science ®Google Scholar
• Ellsberg D. Risk, Ambiguity, and the Savage Axioms. Q J Econ. 1961;75(4):643–669.
   Web of Science ®Google Scholar
• Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. Science. 1974;185(4157):1124–1131.
   PubMed Web of Science ®Google Scholar
• Winickoff RN, Coltin KL, Morgan MM, et al. Improving physician performance through peer comparison feedback. Med Care. 1984;22(6):527–534.
   Google Scholar
• Lip GY, Lane DA. Matching the NOAC to the patient: remember the modifiable bleeding risk factors. J Am Coll Cardiol. 2015;66(21):2282–2284.
   PubMed Web of Science ®Google Scholar
• LaBresh KA, Tyler PA. A collaborative model for hospital-based cardiovascular secondary prevention. Qual Manag Health Care. 2003;12(1):20–27.
   PubMedGoogle Scholar
• Lewis WR, Fonarow GC, Grau-Sepulveda MV, et al. Improvement in use of anticoagulation therapy in patients with ischemic stroke: results from Get With The Guidelines-Stroke. Am Heart J. 2011;162(4):692–9 e2.
   PubMed Web of Science ®Google Scholar
• Lewis WR, Piccini JP, Turakhia MP, et al. Get With The Guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2014;7(5):770–777.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Lewis WR, LaBresh KA, et al. Hospital performance recognition with the get with the guidelines program and mortality for acute myocardial infarction and heart failure. Am Heart J. 2009;158(4):546–553.
   PubMed Web of Science ®Google Scholar
• Pollack CV Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–520.
   PubMed Web of Science ®Google Scholar
• Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor XA inhibitor activity. N Engl J Med. 2015;373(25):2413–2424.
   PubMed Web of Science ®Google Scholar
• Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22):2141–2142.
   PubMed Web of Science ®Google Scholar
• Bronstein AC, Spyker DA, Cantilena LR Jr., et al. 2011 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Philadelphia, Pa). 2012;50(10):911–1164.
   PubMed Web of Science ®Google Scholar
• Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368(14):1272–1274.
   PubMed Web of Science ®Google Scholar
• Ancedy Y, Lecoq C, Saint Etienne C, et al. Antithrombotic management in patients with atrial fibrillation undergoing coronary stent implantation: what is the impact of guideline adherence? Int J Cardiol. 2015;203:987–994.
   PubMed Web of Science ®Google Scholar
• Singh SM, Wijeysundera HC. Cost-effectiveness of novel oral anticoagulants for stroke prevention in non-valvular atrial fibrillation. Curr Cardiol Rep. 2015;17(8):61.
   PubMed Web of Science ®Google Scholar